Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits

• Main Authors: Drobnjak T, Meiri H, Mandalà M, Huppertz B, Gizurarson S
• Format: Article in Journal/Newspaper
• Language: English
• Published: Dove Medical Press 2018
• Subjects: Pharmacokinetics; Placental Protein 13 (PP13); preeclampsia; pregnancy; Therapeutics. Pharmacology; RM1-950; New Zealand; Iceland
• Online Access: https://doaj.org/article/d1394457a36f4e46abbb30b9fa645408

Tijana Drobnjak,1 Hamutal Meiri,2,3 Maurizio Mandalá,4 Berthold Huppertz,5 Sveinbjörn Gizurarson1 1Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland; 2Hy Laboratories, Rehovot, Israel; 3TeleMarpe Ltd., Tel Aviv, Israel; 4Department of Biology, Ecology and Earth Sciences, University of Calabria, Rende, Italy; 5Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia. Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model. Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p<0.01). PP13 elimination half-life was also found to be different between the groups (p<0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%. Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated. Keywords: PP13, ELISA, PK, eNOS, prostaglandin, preeclampsia